Saturday 17 October 2026 Export CNTB’s income statement to Excel — free account

Connect Biopharma Holdings Limited Sponsored ADR

Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.91 0.00 0.00%

Follow CNTB

Alert me

Market cap: $57.1M
P/E: 0.0×
Fwd P/E: −2.0×
Dividend yield: —
F-score: n/a
Altman Z: −5.94
Beneish M: 681.78
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 4.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	1	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 73.76%

Capital & Financial Ratios $m

Market Cap 57.06

Revenue 3.00

Net Income (68.99)

Free Cash Flow (60.58)

Net Debt (31.28)

Current Ratio 2.37

Debt/Equity 0.01

P/E ratio 0.00

Fwd P/E (1.97)

P/S ratio 19.07

P/B ratio 2.13

Past 5Y EPS Growth —

This Y EPS Growth 2.45%

Next Y EPS Growth 24.13%

Next Y revenue growth 78,478.13%

Next 5Y EPS Growth 7.94%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 76.33%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	118	94	44	31
Receivables	4	3	7	7
Inventory	—	—	—	—
Other	—	—	—	—
	123	97	51	39

	2023	2024	2025	Q'26
Payables	2	0	2	2
ST’ Debt	—	—	—	—
Other	13	0	0	—
	25	8	14	16

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(35.64%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	3	—	—	—
’25	—	0	0	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(16)	—	—	—
’25	(10)	(13)	(17)	(11)	(51)
’24	(1)	(7)	(13)	(2)	(24)
’23	—	(30)	—	(48)	(48)
’22	—	(51)	—	(98)	(102)
’21	—	(39)	—	(85)	(85)
’20	—	—	—	(26)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(16)	—	—	—
’25	(10)	(13)	(17)	(11)	(52)
’24	(1)	(8)	(13)	(3)	(24)
’23	—	(30)	—	(48)	(45)
’22	—	(53)	—	(102)	(106)
’21	—	(43)	—	(89)	(89)
’20	—	—	—	(28)	(28)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.34)	(0.27)	—	—	—
’25	(0.19)	(0.23)	(0.31)	(0.27)	(1.00)
’24	(0.16)	—	(0.23)	(0.16)	(0.28)
’23	—	(0.56)	—	—	(1.08)
’22	—	(1.12)	—	(1.03)	(2.10)
’21	—	(3.10)	—	(1.05)	(3.90)
’20	—	—	—	—	(4.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	4.06	0.56	0.54	0.90	0.51	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	29.27	5.99	2.84	2.66	3.28
People
People	Employees	—	—	—	—	62	108	100	81	62	64
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.42	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	26	0
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	100.00	100.00
	EBT	—	—	(14)	(24)	(119)	(205)	(118)	(62)	(15)	(55)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	(59.17)	(86,379.69)
	Net income	—	0	(12)	(24)	(119)	(205)	(118)	(62)	(16)	(55)
	Depreciation	—	—	0	0	0	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.47	0.00
	Earnings	—	—	(0.20)	(0.42)	(4.02)	(3.90)	(2.10)	(1.08)	(0.28)	(1.00)
	Cash flow	—	—	(0.18)	(0.23)	(0.86)	(1.64)	(1.84)	(0.87)	(0.43)	(0.92)
	Capex	—	—	0.00	0.00	(0.08)	(0.08)	(0.08)	0.05	(0.01)	(0.01)
	Free cash flow	—	—	(0.18)	(0.23)	(0.94)	(1.71)	(1.92)	(0.81)	(0.44)	(0.93)
	Book value	—	—	(0.32)	(0.74)	(5.28)	5.22	2.86	1.84	1.67	0.75
	Shares, m	—	—	58	58	30	52	55	55	55	56
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	0.00	0.00
	P/S	—	—	—	—	—	—	—	—	0.00	79.23
	P/B	—	—	—	—	—	—	—	—	0.83	3.74
	EV/Sales	—	—	—	—	—	—	—	—	0.00	57.04
	EV/FCF	—	—	—	—	—	—	—	—	0.71	(2.19)
Cash, $m
Cash, $m	Operating cash flow	—	—	(10)	(13)	(26)	(85)	(102)	(48)	(24)	(51)
	Capex	—	—	0	0	(2)	(4)	(4)	3	(1)	0
	Free cash flow	—	—	(10)	(13)	(28)	(89)	(106)	(45)	(24)	(52)
Balance, $m
Balance, $m	Working capital	—	—	64	48	156	257	140	97	88	37
	Total debt	—	—	84	92	0	0	0	0	0	0
	Net debt	—	—	21	44	(157)	(268)	(152)	(118)	(94)	(44)
	Shareholders’ equity	—	—	(19)	(43)	(157)	272	157	101	92	42
Returns, %
Returns, %	ROA	—	—	(35.21)	(40.82)	(108.69)	(89.64)	(50.78)	(41.21)	(13.67)	(70.51)
	ROIC	—	—	0.00	0.00	0.00	(1,355.35)	(1,401.74)	0.00	0.00	0.00
	ROE	—	—	37.93	79.58	119.48	(355.92)	(54.96)	(47.96)	(16.14)	(82.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
XLO Xilio Therapeutics, Inc.	$59.4M	— (loss-making)	— (loss-making)	+131.22% (above 0%: growing)	n/m	−26.23% (below 0%: shrinking)	100.00%	(18.68%)	Compare
GANX Gain Therapeutics, Inc.	$58.1M	— (loss-making)	— (loss-making)	+27.78% (above 0%: growing)	n/m	+8.22% (above 0%: growing)	0.00%	0.00%	Compare
CNTB Connect Biopharma Holdings Limited Sponsored ADR	$57.1M	— (loss-making)	— (loss-making)	+296.56% (above 0%: growing)	n/m	−23.48% (below 0%: shrinking)	100.00%	(635.98%)
TENX Tenax Therapeutics, Inc.	$56.5M	— (loss-making)	—	−77.98% (below 0%: shrinking)	n/m	−125.93% (below 0%: shrinking)	0.00%	0.00%	Compare
ALPS Alps Group Inc.	$56.4M	— (loss-making)	—	—	n/m	−26.48% (below 0%: shrinking)	—	0.00%	Compare
ELOX Senesco Technologies Inc.	$55.3M	— (loss-making)	—	—	n/m	−144.34% (below 0%: shrinking)	100.00%	0.00%	Compare
GUTS Fractyl Health, Inc.	$55.2M	— (loss-making)	— (loss-making)	−57.14% (below 0%: shrinking)	n/m	+25.34% (above 0%: growing)	100.00%	0.00%	Compare
GOSS Gossamer Bio, Inc.	$54.3M	— (loss-making)	— (loss-making)	−19.59% (below 0%: shrinking)	n/m	+16.32% (above 0%: growing)	100.00%	(282.25%)	Compare
RNTX Rein Therapeutics Inc.	$54.2M	— (loss-making)	—	—	n/m	−34.62% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$55.9M	—	—	−19.59%	—	−26.35%	100.00%	0.00%

All 614 Biotechnology stocks →

Connect Biopharma Holdings Limited Sponsored ADR (CNTB) key facts

Concern: Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024.
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, CNTB traded at $0.91, a market capitalization of $57.1 million.
Return on equity was −82.7% and debt-to-equity 0.01.
Its Altman Z-score is −5.94 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.